european medicines agency · 2o ch 2cho ch 3 ch 2ch 2o h n/2 n/2 m ... control 0.02%p85 1%p85 c p m...

��

��

��

��

��

��

��

��

� ��

��

� �� !"#$%��&'��()�)

��

$* ��+��,-�,�*. ��/ ��+��∼ ,��

��

��

��

�� !"��#��$��%��$��&��

��

��

'��"�

(�"�0

��

)��"��0

��

��

'* "��

�+

,��-.��/ -��$��.��/ ��

,��0�1��2�!��3�� $��1

!"��#�� 4��5�64

��

�� #��1�23�* ��&4(4)�� 5 ��6 ��* � �� &'�(�'��

7��896 "$:

Cl-P

artic

les

Non

Cl-P

artic

les

Free

SO

D1GPC

2. $�� ;��$< ��896 "5 � ��;��6 2� < 6 �� $��

�,��*=�>?,��

� ��;� 100 %

� �#�;��3�� . ��* ��@%��A',�,&�)()��

Control MPTP Nanozyme

2� -6 �� ;��2� ��. ��+;* ��. ��6 =B=6 �� =�

. �� ;�3��6 ��*

"�#��

��

P ≤≤≤≤ nagr precipitation

�� !�!��

++++

- --

--

-+

+

+

+

+

++

--

-

--

+

-

+

++++++

------

-

-

-

-

-+

+

++

+

-

+

nagr ~ 100

'7*

'7*

≈ 5��

≈ 5��

≈ 5��

� ��

�� !��! �

)��(7�

��"

'7* 8�8'�)9:��'�;�

��4��5�

;�� 4��4��45��>64�

Single tail ?��

�+

;��

��=��+��

��

�+

>��=?�C)-�C'

2; ��=D�

B��=E�

Double tail

Triple tail

• +�3��• ��.��1��• ��1�• ��.��• +�!��3��• .08+��

#�� $

2�� 4��6��4��4>�>

Ca2+

=� ;��* � �F* ��

=� ;��-* �� * � �F��

��- ��

�� 3;��3� �� ;* ��

2��- ��

�� ;��

=��3�

2��- ��/ � ��

#��3�� * �23�* �$��',,�&�'�@')A(�')4

��

��

��

��"�!��#��

��$��%&'��()#�

$3� �3��

6 �� F�� ;* ��3

B"6��'G,�'��* @. H4�A

%≅ 4�'�* "I�� * �/ � �� H��4�± ,�4��* ��/ H��,± )�)�*

� !6 �� !6 ��

B�#��3

�� !��*� ��

'��

��)��!��

G. Sahay, et al. Biomaterials, 2009, 31:923-33

MDCK cl-micelles

MDCK TJ MDCK cl-micelles

TJ disrupted

MCF7/ADR cl-micelles

�� %

��" �

�&��'��!�� (�� )��)��

*��'��

��" �� +��)��+" ��,-�.

� -#/� #*0,1-2

MCF7/ADR

1 hr

MCF7/ADR

5 hr

Cross-linked swollen

ionic core

Protective shell

��-< ��*J �$3;

NH2SS

NH2

��!��#��

�+'��,

#��3�� * �23�* �$��',,�&�'�@')A(�')4

#�!� !��$" ��

@

'��$��

'�)��+

?0�?0�

'�:

:A

��+.��

?0�?0�

'�A

#��.��

��!" ��)� ��'�� " ��1�03�

100 nm

vc

2� �� +��/ ��3 ;��* ��

0

20

40

60

80

100

0 36 72 108 144

Time (hours)

% o

f rel

ease

�,* 6 J $�

/ ��3��J $�

0

20

40

60

80

100

120

0.001 0.01 0.1 1 10 100 1000[CDDP], ug/ml

Sur

viva

l (%

)

��+'��

��8$�1��$��

��

�8��+'�

$�1��$��

��

�8��+'�

B�#��3&�-< ��* �� < ��&',,�

� �< �� -< ��*B�#��3

Sahay et al. Bioconjug. Chemistry, 2008, 19(10):1987-94

��!��!��

��

HO CH2CH2O CH2CHO

CH3

CH2CH2O Hn/2 n/2

m

��

0

40

80

120

160

0 20 40 60 80 100 120Time, min

Mic

rovi

scos

ity, %

of c

ontr

ol

L44

F88

L121

P85L81

Batrakova et al. JPET, 2001, 299, 483

��-��!��$��%

==<

="< ="<

�*� ��

J �$3;

��!��!�� .��

��

0

20

40

60

80

100

0.001 0.1 10

[Daunorubicin], mg/ml

Inhi

bitio

n, %

��

��!"��!"#��#��

�$��%��

Alakhova et al, J. Contr, Release2010, online

��&��&��

��'()�*(�

&(�

��!"��#�+��,��

-��

."��

Alakhov et al, Bioconjug. Chem. 1995, 7:209-216

��!��

��*��!��

��!��

//�* �*��

0

4

8

12

16

20

Control 0.02%P85 1%P85

CP

M/m

g tis

sue

**

**16 times

5 times

C57BL/6J mice s.c. Lewis lung carcinoma 3LL-27M

*��

P388/ADR solid tumors

Localized 31P Spectroscopy ISIS Image guided volume Selective In-vivo Spectroscopy

Batrakova et al, J. Contr, Release2010, online

��012/�-

��

The BiotransportThe BiotransportThe BiotransportTMTMTM Technology Company Technology Company Technology Company

%-4�K �,L ��=< =&�,L ��=< "&6 * D'&,,,��

!�'�K ),L ��=< =&�,L ��=< "&6 * D�'&,,,��

HO CH2CH2O CH2CHO

CH3

CH2CH2O Hn/2 n/2

m

2 Pluronic block copolymers��F��

Alakhov et al, Coll. Surf. B: Biointerfaces1999, 16:113-134

B�* ��M� �* �

%��6 ��

%%2)%%

��3��!�� 3��!� ��.��

#��4�3�

2��3%��44�86

=��-�

N

��

��

� ��

�!��

" �� # $% ��& ��'( )*+

,�� &� ��


��012/��*��

��!�-5 67

�3��!��4��!��!�

5 �*�&81��9�:

5 �#*&��!��

!/1��9�:

5 ��;� ��<��!��<

!��

��!�� =1��

5 *��!�� !��

5 �!�3�!��3��!�!��-

��

Danson et al. Br. J. Cancer, 2004 90: 2085


��012/��616�>;� ��<��"��"

5 ?��!��!��<

�� !��

5 60�!��!�$0/�3��%

5 8=��9�6 � ��012/��@3@�3��A"��!�7��

5 ��012/�

��

!�3��!��$..28B%

5 ��3�3�/@/7��!��

5 *��!�� -��!��!��

��

5 ?��!��3��!��!��-

5 ��!��"�!��!��

��=?>

�0�!��!��

5 )��9��(��. �/ ��',�,!��'��

��9(��3��3�@

��(��

-� ��.'&��&��

��&��+

'# ��+�- ��.'��

��/+

��& � ��

��&��

�� &�

� ��

0��&��&��&��

% # $ ��&��

�� &��

�� !��&��

��& ��!�0��&��/

?��-'��<'��<'�?<��<��!��!�� .��)��'��!�� '��

european medicines agency · 2o ch 2cho ch 3 ch 2ch 2o h n/2 n/2 m ... control 0.02%p85 1%p85 c p m...

Documents